8th Sep 2005 14:25
Skyepharma PLC08 September 2005 For Immediate Release 8 September 2005 SKYEPHARMA TO HOST ANALYST PRESENTATION AND CONFERENCE CALL ON 28 SEPTEMBER ON ANNOUNCEMENT OF THE 2005 INTERIM RESULTS LONDON & NEW YORK, 8 September 2005 - As previously announced, SkyePharma PLC(LSE: SKP; Nasdaq: SKYE) will release its Interim Results for the six monthsended 30 June 2005 to the London Stock Exchange at 07:00 a.m. (BST) on Wednesday28 September 2005. Later that day Michael Ashton, SkyePharma's Chief ExecutiveOfficer, will host an analyst presentation, which will be webcast live, and a USconference call to review these results. Investors and other interested parties may view the live webcast of the analystpresentation at 09:00 (BST) on the Company's website at www.skyepharma.com underthe Investor Relations tab. US Investors and other interested parties may access the conference call at 10:00 EDT (15:00 BST) by dialling (800)-230-1074 for US participants and+1-612-234-9960 for international participants. The slides of the presentationwill be available on the Company's website at www.skyepharma.com under theInvestor Relations tab. For those unable to listen to the live broadcast, a replay will be availableshortly after the conference call by dialling (800)-475-6701 for US participantsor +1-320-365-3844 for international participants and entering Access Code795375. For further information please contact: SkyePharma PLC +44 207 491 1777Michael Ashton, Chief Executive OfficerPeter Laing, Director of Corporate Communications +44 207 491 5124 Sandra Haughton, US Investor Relations +1 212 753 5780 Buchanan Communications +44 207 466 5000Tim Anderson / Mark Court/ Rebecca Skye Dietrich About SkyePharma PLC SkyePharma PLC develops pharmaceutical products benefiting from world-leadingdrug delivery technologies that provide easier-to-use and more effective drugformulations. There are now eleven approved products incorporating SkyePharma'stechnologies in the areas of oral, injectable, inhaled and topical delivery,supported by advanced solubilisation capabilities. For more information, visitwww.skyepharma.com. Except for the historical information herein, the matters discussed in this newsrelease include forward-looking statements that may involve a number of risksand uncertainties. Actual results may vary significantly based upon a number offactors, which are described in SkyePharma's 20-F and other documents on filewith the SEC. These include without limitation risks in obtaining andmaintaining regulatory approval for existing, new or expanded indications forits products, other regulatory risks, risks relating to SkyePharma's ability tomanufacture pharmaceutical products on a large scale, risks that customerinventory will be greater than previously thought, risks concerning SkyePharma'sability to manage growth, SkyePharma's marketing partners' ability to market apharmaceutical product on a large scale and manage their sales and marketingorganisation and maintain or expand sales and market share for its products,risks relating to the ability to ensure regulatory compliance, risks related tothe research, development and regulatory approval of new pharmaceuticalproducts, risks related to research and development costs and capabilities,market acceptance of and continuing demand for SkyePharma's products and theimpact of increased competition, risks associated with anticipated top andbottom line growth and the possibility that upside potential will not beachieved, competitive products and pricing, and risks associated with theownership and use of intellectual property rights. SkyePharma undertakes noobligation to revise or update any such forward-looking statement to reflectevents or circumstances after the date of this release. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L